KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Short-term Investments (2021 - 2025)

AbCellera Biologics (ABCL) has disclosed Short-term Investments for 5 consecutive years, with $25.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments changed 0.0% year-over-year to $25.0 million, compared with a TTM value of $25.0 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $25.0 million, changed 0.0% over the prior year.
  • Short-term Investments was $25.0 million for Q3 2025 at AbCellera Biologics, roughly flat from $25.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $25.0 million in Q4 2021 and bottomed at $25.0 million in Q4 2021.
  • Average Short-term Investments over 5 years is $25.0 million, with a median of $25.0 million recorded in 2021.
  • Peak annual rise in Short-term Investments hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
  • Year by year, Short-term Investments stood at $25.0 million in 2021, then changed by 0.0% to $25.0 million in 2022, then changed by 0.0% to $25.0 million in 2023, then changed by 0.0% to $25.0 million in 2024, then changed by 0.0% to $25.0 million in 2025.
  • Business Quant data shows Short-term Investments for ABCL at $25.0 million in Q3 2025, $25.0 million in Q2 2025, and $25.0 million in Q1 2025.